Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
Ionis Pharmaceuticals, Inc. is a RNA-targeted drug discovery and development company which focuses on developing drugs for severe and rare diseases. Ionis Pharmaceuticals, Inc., formerly known as Isis Pharmaceuticals, Inc., is headquartered in Carlsbad, California.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)’s Financial Overview
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) declined -5.42% yesterday to close its trading session at $43.76. The company has 1 year Price Target of $43.3. Ionis Pharmaceuticals, Inc. has 52-Week high of $62.68 and 52-Week Low of $19.59. The stock touched its 52-Week High on Jan 5, 2016 and 52-Week Low on May 27, 2016. The stock traded with the volume of 1.77 Million shares yesterday. The firm shows the market capitalization of $5.3 Billion.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) reported its last quarterly earnings on Sep 16 where the firm reported its Actual EPS of $0.06/share against the analyst consensus estimate of $0.08/share. The difference between the actual and expected EPS is $-0.02 a share with a surprise factor of -25%.
The firm is trading with SMA20 of 9.47 Percent, SMA50 of 24.76 Percent and SMA200 of 31.05 percent. Ionis Pharmaceuticals, Inc. has P/S value of 22.3 while its P/B value stands at 38.05. Similarly, the company has Return on Assets of -21.1 percent, Return on Equity of -120.6 percent and Return on Investment of -11.3 Percent. The company shows Gross Margin and Operating Margin of -22.2 percent and -63.2 percent respectively.
Many brokerage firms are involved in issuing their ratings on Ionis Pharmaceuticals, Inc. (NASDAQ:IONS). On 3-Aug-16 Morgan Stanley Initiated Ionis Pharmaceuticals, Inc. Stock to Equal-Weight.
The Stock currently has Analyst’ mean Recommendation of 2.5 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.
The 12 analysts offering 12-month price forecasts for Ionis Pharmaceuticals Inc have a median target of 41.00, with a high estimate of 64.00 and a low estimate of 17.00. The median estimate represents a -6.31% decrease from the last price of 43.76.
Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.
The Goldman Sachs Group, Inc. (NYSE:GS)
Goldman Sachs is a global investment banking and securities firm, providing a full range of investing, advisory and financing services worldwide to a substantial and diversified client base, which includes corporations, financial institutions, governments, and high net worth individuals. (Company Press Release)
The Goldman Sachs Group, Inc. (NYSE:GS)’s Financial Outlook
The 23 analysts offering 12-month price forecasts for Goldman Sachs have a median target of 195.00, with a high estimate of 245.00 and a low estimate of 120.00. The median estimate represents a -11.08% decrease from the last price of 219.29.
Goldman Sachs Group, Inc. (The) is estimated to report earnings on 01/18/2017. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates.Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 8 analysts’ forecasts, the consensus EPS forecast for the quarter is $4.42. The reported EPS for the same quarter last year was $4.68.
According to Zacks Investment Research, The Goldman Sachs Group, Inc. has a Consensus Recommendation of 2.41. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).
The Stock gained 3.56% and closed its last trading session at $219.29. The company has the market capitalization of $87.2 Billion. The stock has 52-week high of $220.77 and 52-Week low of $138.2. The firm touched its 52-Week high on Nov 30, 2016 and 52-Week low on Jun 27, 2016. The company has volume of 6.49 Million shares. The company has a total of 397.65 Million shares outstanding.
The Goldman Sachs Group, Inc. (NYSE:GS) in the last quarter reported its actual EPS of $4.88/share where the analyst estimated EPS was $3.82/share. The difference between the actual and Estimated EPS is $1.06. This shows a surprise factor of 27.7 percent.
The company has YTD performance of 23.56 percent. Beta for The Goldman Sachs Group, Inc. stands at 1.59 while its ATR (average true range) is 4.15. The company has Weekly Volatility of 1.58%% and Monthly Volatility of 2.11%%.
The Goldman Sachs Group, Inc. has distance from 20-day Simple Moving Average (SMA20) of 10.46%, Distance from 50-Day Simple Moving Average of 21.43 percent and Distance from 200-Day Simple Moving Average of 35.11%.
The Company currently has ROA (Return on Assets) of 0.6 percent, Return on Equity (ROE) of 7.3 Percent and Return on Investment (ROI) of 1.1% with Gross margin of 72.7 percent and Operating & Profit margin of 21.9% and 15.1% respectively.